Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

57318 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ZIDOVUDINE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE STAVUDINE ABACAVIR AND LAMIVUDINE ABACAVIR SULFATE AND LAMIVUDINE DIDANOSINE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	FOETAL EXPOSURE DURING PREGNANCY	2967
1	DRUG EXPOSURE DURING PREGNANCY	2442
2	PYREXIA	2207
3	NAUSEA	2191
4	DIARRHOEA	2085
5	DRUG INTERACTION	2000
6	ANAEMIA	1912
7	VOMITING	1853
8	DRUG RESISTANCE	1626
9	FATIGUE	1504

See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	IMMUNE RECONSTITUTION SYNDROME	908	0.7264
1	BLOOD HIV RNA INCREASED	305	0.7227
2	HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION	93	0.6370
3	LIPODYSTROPHY ACQUIRED	630	0.5812
4	MITOCHONDRIAL TOXICITY	218	0.5619
5	VIROLOGIC FAILURE	1015	0.5007
6	ACQUIRED GENE MUTATION	83	0.4029
7	FANCONI SYNDROME ACQUIRED	341	0.3933
8	GENOTYPE DRUG RESISTANCE TEST POSITIVE	181	0.3358
9	IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME	758	0.3344

See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]